BDTX

Black Diamond Therapeutics, Inc. (BDTX) | Rumor.io

Black Diamond Therapeutics

BDTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,913

Bullish sentiment (50-day avg)82%

Price to earnings ratio7.23

Market capitalization105.1M

Earnings per share-0.75

Dividend yield (TTM)—

Revenue (annual)70M

Net income (annual)22.4M

Social

What share of all stock conversation is about BDTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 1

$BDTX was added to the Russell 2000 and 3000 indexes and board members received 40,000 shares, awaiting trial news.
The stock's price has seen a slight sell-off before close every day, but holding and waiting for a potential payoff could be worth it.
$BDTX has the potential to jump above $2 and reach $3 with enough volume, and good news from the trial could send the stock even higher.

Generated by AI

Sentiment

Of the messages about BDTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	72.73% -27.27	87.26% +0
Bearish	0%	0% 0	27.27% +27.27	12.74% 0

Bullish· May 20

$BDTX has been gaining 150% and is expected to continue rising due to its MasterKey therapies targeting genetically defined cancers.
The company's pipeline driver, silevertinib, is expected to deliver Phase 2 data, which could further boost the stock's price.
$BDTX is trading like a classic biotech volatility setup, benefiting from a rebound in market risk appetite toward biotech names, and is expected to continue its upward climb.

Bearish· May 22

The asset's price may be driven down by fear, but it's considered a good investment in the long run.
The company may face challenges in recovering its investment in the partnership with Servier, as they may need to wait for positive IA (or FA) data before making an offer.
The asset's market capitalization is relatively low at $200 million, which may not be a fair value considering the recent run, and a bigger company may be needed to run a phase III trial.

Generated by AI

Topics

Of the messages about BDTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	66.67%	22.65%
Announcements	—	—	33.33%	51.95%
Analysts	—	—	0%	6.86%
Controversies	—	—	0%	0.46%
Earnings	—	—	0%	1.14%
Macro	—	—	0%	16.93%

Announcements· Apr 1

Black Diamond Therapeutics (BDTX) is a clinical stage company developing MasterKey therapies against tumours and cancers in brain and lungs.
The company has one drug under development, currently in Phase 2, and is likely to move into Phase 3/FDA approval request by H1 of next year.
There is an investigation into a large insider trade by a BDTX executive, which occurred a day before a discounted stock offering was announced.

Technical Analysis· Mar 20

BDTX has formed a bullish pennant and is targeting a price of $15.
The stock is heavily shorted at the $2 level, and a squeeze could occur if it breaks above $2.15.
BDTX is forming a bullish flag and has a high short volume ratio, indicating aggressive short-selling and a potential larger upside when the breakout occurs.

Generated by AI

Community

Of the messages about BDTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	55.56%	27.38%	52.2%
Newcomers	0%	44.44%	72.62%	47.8%

Regulars· Sep 23

The initial Phase 2 data for BDTX-1535 demonstrated robust anti-tumor activity in patients with recurrent EGFRm NSCLC, including a 36% overall response rate (ORR) and favorable safety.
Of the 19 patients with known osimertinib resistance, 8 achieved a response (42%), and 14 of 19 patients remain on treatment, with early responders averaging 8 months duration of response (DOR).
The company's stock price is breaking out of its daily chart channel, with potential targets including the 52-week high of $7.66 and $10, with resistance at $6.75 and $7.66.

Newcomers· Jan 13

The newcomer is focusing on whether BDTX is a good buy, analyzing the stock's performance and predicting its future price.
The newcomer is sharing their first trades, including BDTX, and the fact that they only paid $5 for the locates, which may indicate a low-cost or experimental approach to trading.
The newcomer is concerned about the potential for algo engines to be triggered, and is advising others to consider sitting in cash until market volatility settles.

Generated by AI

News

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

25d agoYahoo Finance

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Gl

27d agoYahoo Finance

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)

Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Jefferies reiterates Buy on Black Diamond stock, $10 target

1mo agoInvesting.com

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients with baseline brain metastases achieved a CNS objective response rate of 86%The results position silevertinib as a potential best-in-class brain-penetrant EGFR inhibitor; an update on the Phase 2 trial and FDA feedback on a pivotal development path for silevertinib in frontline pat

1mo agoYahoo Finance

Also Discussed

Investors talking about BDTX also mention

#	Name	Attention
1	Oric Pharmaceuticals, Inc.ORIC	0%0
2	ICCT - iCoreConnect Inc.	——
3	Nuvalent, Inc.NUVL	0%0
4	TCRR - TCR2 Therapeutics Inc.	——
5	Foghorn Therapeutics Inc.FHTX	0%new
6	Cullinan Therapeutics Inc.CGEM	0%new
7	FIAC - Focus Impact Acquisition Corp.	——
8	Annexon Inc.ANNX	0%+0
9	KACL - Kairous Acquisition Corp. Limited	——
10	iShares Core S&P U.S. Value ETFIUSV	0%0

Black Diamond Therapeutics, Inc.

Healthcare
Biotechnology

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers. The company’s current programs center on small-molecule MasterKey therapies designed to target families of oncogenic mutations across multiple tumor types, with an emphasis on overcoming resistance and addressing tumors that are difficult to treat with standard approaches. Its lead clinical asset, silevertinib, is a brain-penetrant EGFR inhibitor being studied in non-small cell lung cancer and glioblastoma. Black Diamond Therapeutics also advances additional oncology candidates in its pipeline aimed at other mutation-driven solid tumors. Based in Cambridge, Massachusetts, the company plays a role in the biotechnology market as a developer of targeted cancer therapies intended for patients whose tumors are driven by specific genetic alterations.

Website

Location

245 First Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about BDTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 1

$BDTX was added to the Russell 2000 and 3000 indexes and board members received 40,000 shares, awaiting trial news.
The stock's price has seen a slight sell-off before close every day, but holding and waiting for a potential payoff could be worth it.
$BDTX has the potential to jump above $2 and reach $3 with enough volume, and good news from the trial could send the stock even higher.

Generated by AI

Sentiment

Of the messages about BDTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	72.73% -27.27	87.26% +0
Bearish	0%	0% 0	27.27% +27.27	12.74% 0

Bullish· May 20

$BDTX has been gaining 150% and is expected to continue rising due to its MasterKey therapies targeting genetically defined cancers.
The company's pipeline driver, silevertinib, is expected to deliver Phase 2 data, which could further boost the stock's price.
$BDTX is trading like a classic biotech volatility setup, benefiting from a rebound in market risk appetite toward biotech names, and is expected to continue its upward climb.

Bearish· May 22

The asset's price may be driven down by fear, but it's considered a good investment in the long run.
The company may face challenges in recovering its investment in the partnership with Servier, as they may need to wait for positive IA (or FA) data before making an offer.
The asset's market capitalization is relatively low at $200 million, which may not be a fair value considering the recent run, and a bigger company may be needed to run a phase III trial.

Generated by AI

Topics

Of the messages about BDTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	66.67%	22.65%
Announcements	—	—	33.33%	51.95%
Analysts	—	—	0%	6.86%
Controversies	—	—	0%	0.46%
Earnings	—	—	0%	1.14%
Macro	—	—	0%	16.93%

Announcements· Apr 1

Black Diamond Therapeutics (BDTX) is a clinical stage company developing MasterKey therapies against tumours and cancers in brain and lungs.
The company has one drug under development, currently in Phase 2, and is likely to move into Phase 3/FDA approval request by H1 of next year.
There is an investigation into a large insider trade by a BDTX executive, which occurred a day before a discounted stock offering was announced.

Technical Analysis· Mar 20

BDTX has formed a bullish pennant and is targeting a price of $15.
The stock is heavily shorted at the $2 level, and a squeeze could occur if it breaks above $2.15.
BDTX is forming a bullish flag and has a high short volume ratio, indicating aggressive short-selling and a potential larger upside when the breakout occurs.

Generated by AI

Community

Of the messages about BDTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	55.56%	27.38%	52.2%
Newcomers	0%	44.44%	72.62%	47.8%

Regulars· Sep 23

The initial Phase 2 data for BDTX-1535 demonstrated robust anti-tumor activity in patients with recurrent EGFRm NSCLC, including a 36% overall response rate (ORR) and favorable safety.
Of the 19 patients with known osimertinib resistance, 8 achieved a response (42%), and 14 of 19 patients remain on treatment, with early responders averaging 8 months duration of response (DOR).
The company's stock price is breaking out of its daily chart channel, with potential targets including the 52-week high of $7.66 and $10, with resistance at $6.75 and $7.66.

Newcomers· Jan 13

The newcomer is focusing on whether BDTX is a good buy, analyzing the stock's performance and predicting its future price.
The newcomer is sharing their first trades, including BDTX, and the fact that they only paid $5 for the locates, which may indicate a low-cost or experimental approach to trading.
The newcomer is concerned about the potential for algo engines to be triggered, and is advising others to consider sitting in cash until market volatility settles.

Generated by AI

Black Diamond Therapeutics

Social

Jul 1

Bullish· May 20

Bearish· May 22

Announcements· Apr 1

Technical Analysis· Mar 20

Regulars· Sep 23

Newcomers· Jan 13

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)

Jefferies reiterates Buy on Black Diamond stock, $10 target

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Black Diamond Therapeutics, Inc.

Company Information

Location

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)

Jefferies reiterates Buy on Black Diamond stock, $10 target

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Social

Jul 1

Bullish· May 20

Bearish· May 22

Announcements· Apr 1

Technical Analysis· Mar 20

Regulars· Sep 23

Newcomers· Jan 13